Elizabeth Garrett-Mayer
Affiliations: | Medical University of South Carolina, Charleston, SC, United States |
Area:
Biostatistics BiologyGoogle:
"Elizabeth Garrett-Mayer"Children
Sign in to add trainee| Emily M. Van Meter | grad student | 2010 | MUSC |
| Cody C. Chiuzan | grad student | 2014 | MUSC |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hopkins AM, Kichenadasse G, Garrett-Mayer E, et al. (2020) Development and validation of a prognostic model for patients with advanced lung cancer treated with the immune checkpoint inhibitor atezolizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Meiri E, Garrett-Mayer E, Halabi S, et al. (2020) Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Journal of Clinical Oncology. 38: 133-133 |
| Gupta R, Garrett-Mayer E, Halabi S, et al. (2020) Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study. Journal of Clinical Oncology. 38: 132-132 |
| Klute K, Garrett-Mayer E, Halabi S, et al. (2020) Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study. Journal of Clinical Oncology. 38: 122-122 |
| Kushi LH, Lasiter L, Belli AJ, et al. (2020) Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data. Journal of Clinical Oncology. 38: e19311-e19311 |
| Smith ML, Railey E, White CB, et al. (2020) NGS testing use and results: A survey of U.S. oncologists. Journal of Clinical Oncology. 38: e19145-e19145 |
| Alpert A, Bruinooge SS, Dizon DS, et al. (2020) Identification of transgender people with cancer in electronic health records (EHR): Recommendations based on CancerLinQ observations. Journal of Clinical Oncology. 38: e19046-e19046 |
| Potter D, Kaltenbaugh M, Kabadi S, et al. (2020) Vital status ascertainment in cancerlinq discovery (CLQD): Improvement in mortality capture with a supplemental data source. Journal of Clinical Oncology. 38: 7064-7064 |
| Ahn ER, Garrett-Mayer E, Halabi S, et al. (2020) Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Journal of Clinical Oncology. 38: 4637-4637 |
| Walter KR, Ford FE, Gregoski MJ, et al. (2020) Abstract C024: Lifestyle-associated advanced glycation end products are elevated in ER+ positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention Cancer Epidemiology, Biomarkers & Prevention. 29 |